TBPH vs. STTK, SLRN, IGMS, TVTX, ANL, FULC, TRDA, APLT, KALV, and CDMO
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Shattuck Labs (STTK), Acelyrin (SLRN), IGM Biosciences (IGMS), Travere Therapeutics (TVTX), Adlai Nortye (ANL), Fulcrum Therapeutics (FULC), Entrada Therapeutics (TRDA), Applied Therapeutics (APLT), KalVista Pharmaceuticals (KALV), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma (NASDAQ:TBPH) and Shattuck Labs (NASDAQ:STTK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.
Theravance Biopharma has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
Theravance Biopharma has a net margin of -96.12% compared to Shattuck Labs' net margin of -5,268.44%. Theravance Biopharma's return on equity of -19.31% beat Shattuck Labs' return on equity.
Theravance Biopharma has higher revenue and earnings than Shattuck Labs. Theravance Biopharma is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.
99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 6.9% of Theravance Biopharma shares are owned by company insiders. Comparatively, 9.9% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Theravance Biopharma currently has a consensus target price of $20.50, suggesting a potential upside of 124.78%. Shattuck Labs has a consensus target price of $20.00, suggesting a potential upside of 88.86%. Given Theravance Biopharma's higher possible upside, research analysts plainly believe Theravance Biopharma is more favorable than Shattuck Labs.
Theravance Biopharma received 309 more outperform votes than Shattuck Labs when rated by MarketBeat users. However, 73.53% of users gave Shattuck Labs an outperform vote while only 63.38% of users gave Theravance Biopharma an outperform vote.
In the previous week, Theravance Biopharma and Theravance Biopharma both had 1 articles in the media. Theravance Biopharma's average media sentiment score of 0.00 equaled Shattuck Labs'average media sentiment score.
Summary
Theravance Biopharma beats Shattuck Labs on 9 of the 14 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
